Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

NCT02655887 · View on ClinicalTrials.gov ↗

Study Summary

The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.

Interventions

  • DEVICE VENOVO™ Venous Stent

Study Locations (20)

Other

  • Uniklinik RWTH — Aachen
  • Klinikum Arnberg — Arnsberg
  • Universitaets-Herrzentrum Freiburg-Bad Krozingen — Bad Krozingen
  • University Hospital Galway — Galway
  • MUMC Maastricht — Maastricht
  • Fundacion de investigacion HM Hospitales — Madrid

Connecticut

  • Vascular Breakthroughs, LLC — Darien
  • Yale University — New Haven

Virginia

  • Centra Health, Inc., dba Stroobants Cardiovascular Center — Lynchburg
  • Sentara Medical Group — Virginia Beach

Iowa

  • Midwest Cardiovascular Research Foundation — Davenport

Michigan

  • Metro Health Hospital — Wyoming

Missouri

  • Cox Medical Centers — Springfield

New York

  • Mount Sinai Medical Center — New York

North Carolina

  • North Carolina Heart and Vascular — Raleigh

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2016-06-15
Est. Completion 2020-10-30
Phase NA

Sponsor

C. R. Bard

46 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02655887

The ClinicalTrials.gov registry entry for NCT02655887 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 46 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention — of which VENOVO™ Venous Stent is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02655887 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Other, Connecticut, Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02655887 about?

NCT02655887 is a clinical study titled "BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease". The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.

What is the current status of trial NCT02655887?

This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2016-06-15. Estimated completion is 2020-10-30.

What conditions does trial NCT02655887 study?

This clinical trial studies the following conditions: Peripheral Vascular Disease, Venous Disease, May-Thurner Syndrome, Iliofemoral Occlusive Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02655887?

The interventions under investigation include: VENOVO™ Venous Stent (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02655887?

This trial is sponsored by C. R. Bard, which has 46 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02655887 being conducted?

This trial has 20 study locations across Connecticut, Iowa, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial